Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRRO NASDAQ:SLDB NASDAQ:TERN NASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRROKorro Bio$15.90-5.6%$13.38$10.29▼$98.00$158.23M2.43122,505 shs144,741 shsSLDBSolid Biosciences$6.68-1.2%$4.48$2.41▼$10.37$524M2.341.71 million shs1.58 million shsTERNTerns Pharmaceuticals$6.06-0.5%$4.08$1.87▼$11.40$531.88M-0.11940,793 shs743,218 shsTRMLTourmaline Bio$18.75-1.0%$17.40$11.56▼$29.79$486.48M2143,628 shs251,649 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRROKorro Bio+18.75%+28.04%+43.40%-3.38%-64.42%SLDBSolid Biosciences+8.51%+21.15%+49.89%+84.20%-26.52%TERNTerns Pharmaceuticals+1.50%+15.56%+65.49%+99.67%-32.11%TRMLTourmaline Bio+0.42%+2.16%+11.28%+9.35%+22.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRROKorro Bio2.0814 of 5 stars3.61.00.00.03.30.00.6SLDBSolid Biosciences3.2728 of 5 stars4.61.00.00.03.11.70.6TERNTerns Pharmaceuticals3.6241 of 5 stars3.31.00.04.11.13.30.0TRMLTourmaline Bio2.1058 of 5 stars3.51.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRROKorro Bio 3.29Buy$102.43544.20% UpsideSLDBSolid Biosciences 3.17Buy$15.10126.05% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63157.84% UpsideTRMLTourmaline Bio 3.00Buy$49.33163.11% UpsideCurrent Analyst Ratings BreakdownLatest KRRO, SLDB, TERN, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.007/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.005/16/2025SLDBSolid BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $10.005/16/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$18.00 ➝ $17.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRROKorro Bio$2.27M65.77N/AN/A$17.12 per share0.93SLDBSolid Biosciences$8.09M64.00N/AN/A$3.43 per share1.95TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRROKorro Bio-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)TRMLTourmaline Bio-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)Latest KRRO, SLDB, TERN, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TRMLTourmaline Bio-$0.95N/AN/AN/AN/AN/A8/12/2025Q2 2025KRROKorro Bio-$2.54N/AN/AN/A$0.41 millionN/A8/12/2025Q2 2025SLDBSolid Biosciences-$0.51N/AN/AN/AN/AN/A8/4/2025Q2 2025TERNTerns Pharmaceuticals-$0.29N/AN/AN/AN/AN/A5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRROKorro BioN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRROKorro BioN/A9.419.41SLDBSolid BiosciencesN/A10.8910.89TERNTerns PharmaceuticalsN/A30.8930.89TRMLTourmaline BioN/A33.8733.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRROKorro Bio13.18%SLDBSolid Biosciences81.46%TERNTerns Pharmaceuticals98.26%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipKRROKorro Bio4.60%SLDBSolid Biosciences1.90%TERNTerns Pharmaceuticals1.50%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRROKorro Bio709.39 million8.96 millionNo DataSLDBSolid Biosciences10077.51 million76.04 millionOptionableTERNTerns Pharmaceuticals4087.34 million86.03 millionNot OptionableTRMLTourmaline Bio4425.68 million22.35 millionOptionableKRRO, SLDB, TERN, and TRML HeadlinesRecent News About These CompaniesJennison Associates LLC Cuts Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)July 22 at 6:46 AM | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Average Price Target from AnalystsJuly 22 at 2:11 AM | americanbankingnews.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Consensus Rating of "Buy" from BrokeragesJuly 19, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Shares Down 2.1% - Should You Sell?July 16, 2025 | marketbeat.comTourmaline Bio Inc News (TRML) - Investing.comJuly 3, 2025 | investing.comTRML - Tourmaline Bio Inc Dividends - MorningstarJune 26, 2025 | morningstar.comMTRML - Tourmaline Bio Inc Executives - MorningstarJune 24, 2025 | morningstar.comMTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from BrokeragesJune 24, 2025 | marketbeat.comTourmaline Bio Elects Directors and Ratifies AuditorJune 6, 2025 | tipranks.comH.C. Wainwright maintains $50 target on Tourmaline Bio stockMay 29, 2025 | uk.investing.comH.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 ResultsMay 29, 2025 | msn.comBMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)May 23, 2025 | msn.comTourmaline shares waver as investors mull mid-stage pacibekitug dataMay 21, 2025 | thepharmaletter.comTTourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease winMay 20, 2025 | fiercebiotech.comFTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 20, 2025 | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20, 2025 | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19, 2025 | globenewswire.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comWhy Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%May 3, 2025 | aaii.comATourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 3, 2025 | finanznachrichten.deTourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 2, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeBigBear.ai: Why a 90% Rally Could Be Just the StartBy Jeffrey Neal Johnson | July 10, 2025View BigBear.ai: Why a 90% Rally Could Be Just the StartForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffRigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermBy Leo Miller | July 22, 2025View Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-TermCSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025View CSX Stock Rally: Strong Options Flow, Analyst Price TargetsKRRO, SLDB, TERN, and TRML Company DescriptionsKorro Bio NASDAQ:KRRO$15.90 -0.95 (-5.64%) Closing price 04:00 PM EasternExtended Trading$16.14 +0.24 (+1.51%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Solid Biosciences NASDAQ:SLDB$6.68 -0.08 (-1.18%) Closing price 04:00 PM EasternExtended Trading$6.68 0.00 (0.00%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Terns Pharmaceuticals NASDAQ:TERN$6.06 -0.03 (-0.49%) Closing price 04:00 PM EasternExtended Trading$6.07 +0.01 (+0.17%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Tourmaline Bio NASDAQ:TRML$18.75 -0.19 (-1.00%) Closing price 04:00 PM EasternExtended Trading$18.05 -0.70 (-3.73%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
